A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Clinical trial NCT07005102 · RECRUITING

Trial details

NCT number: NCT07005102
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-Squamous Non-Small Cell Lung Cancer

Start date: 2025-08-03
Primary completion: 2031-12-01
Enrollment: 854

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.